MetaVia Advances DA-1726 Obesity Trial to Top Doses
I'm LongbridgeAI, I can summarize articles.MetaVia announced that all active patients in Part 3 of its Phase 1 trial for obesity drug DA-1726 have completed dose titration and are receiving top doses (48 mg and 64 mg). This progress highlights the drug's favorable tolerability. The company expects to release topline data in Q4 2026, detailing safety and pharmacokinetics. While analysts rate the stock a Buy with an $8 target, AI analysis suggests Neutral due to weak financials and technical indicators.
MetaVia ( (MTVA) ) just unveiled an update.
On July 9, 2026, MetaVia announced that all enrolled active patients in Part 3 of its Phase 1 clinical trial of DA-1726 for obesity have successfully completed dose titration and are now receiving the highest target doses of 48 mg and 64 mg. Part 3 comprises two 16-week titration cohorts testing one-step and two-step dose-escalation strategies, with approximately 40 obese but otherwise healthy adults randomized 4:1 between active treatment and placebo.
The company highlighted that reaching top dose levels in all active patients underscores a favorable tolerability profile and may offer a competitive edge versus currently marketed obesity drugs. With all subjects now on target doses, MetaVia plans to complete treatment and deliver topline Phase 1 Part 3 data in the fourth quarter of 2026, data that will further define DA-1726’s safety, pharmacokinetics and cardiometabolic effects for investors and partners monitoring its progress in the obesity drug race.
The most recent analyst rating on (MTVA) stock is a Buy
with a $8.00 price target.
To see the full list of analyst forecasts on MetaVia stock,
see the MTVA Stock Forecast page.
Spark’s Take on MTVA Stock
According to Spark, TipRanks’ AI Analyst, MTVA is a Neutral.
The score is primarily held back by weak financial fundamentals (no revenue, persistent losses, and ongoing cash burn with likely financing needs) and poor technical conditions (below key moving averages with negative MACD). Positive clinical/pipeline announcements provide some support, but dilution risk from the at-the-market offering and limited valuation anchors (negative P/E, no dividend) keep the overall score low.
To see Spark’s full report on MTVA stock,
click here.
More about MetaVia
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, with a primary emphasis on obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH). Its lead candidates include DA-1726, a once-weekly oxyntomodulin analogue acting as a dual GLP-1/glucagon receptor agonist for obesity and MASH, and vanoglipel, a GPR119-targeting agent aimed at improving metabolic and hepatic outcomes.
Average Trading Volume: 3,831,964
Technical Sentiment Signal: Strong Sell
Current Market Cap: $8.06M
Find detailed analytics on MTVA stock on TipRanks’ Stock Analysis page.